132 related articles for article (PubMed ID: 28073907)
1. Metformin prevents metabolic side effects during systemic glucocorticoid treatment.
Seelig E; Meyer S; Timper K; Nigro N; Bally M; Pernicova I; Schuetz P; Müller B; Korbonits M; Christ-Crain M
Eur J Endocrinol; 2017 Mar; 176(3):349-358. PubMed ID: 28073907
[TBL] [Abstract][Full Text] [Related]
2. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
Pernicova I; Kelly S; Ajodha S; Sahdev A; Bestwick JP; Gabrovska P; Akanle O; Ajjan R; Kola B; Stadler M; Fraser W; Christ-Crain M; Grossman AB; Pitzalis C; Korbonits M
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):278-291. PubMed ID: 32109422
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
4. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
5. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial.
van Raalte DH; Diamant M; Ouwens DM; Ijzerman RG; Linssen MM; Guigas B; Eringa EC; Serné EH
Diabetologia; 2013 Nov; 56(11):2383-91. PubMed ID: 23933953
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
9. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
12. Metabolic complications of glucocorticoids - Prevention by metformin.
Sanpawithayakul K; Korbonits M
Ann Endocrinol (Paris); 2023 Aug; 84(4):483-497. PubMed ID: 37209947
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
14. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
Rissanen A; Howard CP; Botha J; Thuren T;
Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
[TBL] [Abstract][Full Text] [Related]
15. The effect of metformin on glucose metabolism in patients receiving glucocorticoids.
Landis D; Sutter A; Fernandez F; Nugent K
Am J Med Sci; 2022 Oct; 364(4):379-385. PubMed ID: 35525318
[TBL] [Abstract][Full Text] [Related]
16. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
18. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica.
Dasgupta B; Dolan AL; Panayi GS; Fernandes L
Br J Rheumatol; 1998 Feb; 37(2):189-95. PubMed ID: 9569075
[TBL] [Abstract][Full Text] [Related]
19. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
Niewoehner DE; Erbland ML; Deupree RH; Collins D; Gross NJ; Light RW; Anderson P; Morgan NA
N Engl J Med; 1999 Jun; 340(25):1941-7. PubMed ID: 10379017
[TBL] [Abstract][Full Text] [Related]
20. Metformin's effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers.
Ochola LA; Nyamu DG; Guantai EM; Weru IW
J Oncol Pharm Pract; 2020 Jun; 26(4):823-834. PubMed ID: 31495292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
